Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of PT2385 in Healthy Volunteers
NCT02553356Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2015
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of PT-2385 in renal cell carcinoma (RCC) (2 arms), sponsored by Merck & Co. Primary endpoint: Maximum Plasma Concentration at 6 days. Started Sep 2015; status: completed.
02
Drugs
PT-2385
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02553356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02553356.